Production (Stage)
Jasper Therapeutics, Inc.
JSPR
$6.03
$0.020.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -78.78M | -71.27M | -63.53M | -62.44M | -63.93M |
| Total Depreciation and Amortization | 1.36M | 1.37M | 1.41M | 1.15M | 1.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.82M | 7.10M | 6.23M | 5.30M | 4.77M |
| Change in Net Operating Assets | -110.00K | 193.00K | -2.06M | 118.00K | 576.00K |
| Cash from Operations | -69.71M | -62.60M | -57.95M | -55.88M | -57.47M |
| Capital Expenditure | -527.00K | -552.00K | -686.00K | -412.00K | -266.00K |
| Sale of Property, Plant, and Equipment | 24.00K | 20.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -503.00K | -532.00K | -686.00K | -412.00K | -266.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 535.00K | 47.88M | 47.57M | 47.59M | 47.77M |
| Repurchase of Common Stock | -- | -- | -299.00K | -299.00K | -960.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 535.00K | 47.88M | 47.27M | 47.30M | 46.81M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -69.68M | -15.25M | -11.37M | -8.99M | -10.93M |